Skip to content

Study · Not a test of the peptide alone · 1996

3 results

Combination thymosin alpha 1 and lymphoblastoid interferon treatment in chronic hepatitis C.

Rasi G, DiVirgilio D, Mutchnick MG, Colella F, Sinibaldi-Vallebona P, Pierimarchi P, Valli B, Garaci E

Gut1 Nov 1996Cited by 34 (Europe PMC)

PMID9026482 (opens in a new tab)PMCIDPMC1383391 (opens in a new tab)DOI10.1136/gut.39.5.679 (opens in a new tab)PepBankPUB-09026482
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 01HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialEfficacy outcome

    In patients with chronic hepatitis C, combination thymosin alpha‑1 and lymphoblastoid interferon left seven patients (47%) serum HCV RNA negative six months after start.

    In plain wordsIn patients with hepatitis C, a thymosin alpha‑1 plus interferon regimen was followed by a negative virus test in 47% at six months.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseSerum HCV RNA negative at 6 months after treatment start
    Study

    n = 15

    Outcome group
    Antiviral activity · Infection

    Measurements

    Patients HCV RNA negative
    47%
    6 months after initiation

    Source sentences

    Summary
    Six months after initiation of treatment seven patients (47%) were sera HCV RNA negative
    2 context sentences
    Summary · context
    To assess the response in patients with chronic hepatitis C to one year of combination treatment: thymosin alpha 1 (T alpha 1), 1 mg twice weekly, and lymphoblastoid (L)-IFN, 3 MU thrice weekly.
    Summary · context
    Fifteen patients with serum HCV RNA positive chronic hepatitis C were studied.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  2. 02HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialEfficacy outcome

    In patients with chronic hepatitis C, combination thymosin alpha‑1 and lymphoblastoid interferon left 11 patients (73%) serum HCV RNA negative at the end of one year, including two who failed earlier interferon.

    In plain wordsIn patients with hepatitis C, a thymosin alpha‑1 plus interferon regimen was followed by a negative virus test in 73% after one year.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseSerum HCV RNA negative at end of one year treatment
    Study

    n = 15

    Outcome group
    Antiviral activity · Infection

    Measurements

    Patients HCV RNA negative
    73%
    end of 1 year treatment

    Source sentences

    Summary
    at completion of the one year treatment 11 (73%), including two who had failed previous standard IFN treatment, had negative serum HCV RNA.
    2 context sentences
    Summary · context
    To assess the response in patients with chronic hepatitis C to one year of combination treatment: thymosin alpha 1 (T alpha 1), 1 mg twice weekly, and lymphoblastoid (L)-IFN, 3 MU thrice weekly.
    Summary · context
    Fifteen patients with serum HCV RNA positive chronic hepatitis C were studied.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  3. 03HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialEfficacy outcome

    In patients with chronic hepatitis C, combination thymosin alpha‑1 and lymphoblastoid interferon gave a sustained response in six patients (40%) six months after treatment, including five with HCV type 1b.

    In plain wordsIn patients with hepatitis C, a thymosin alpha‑1 plus interferon regimen was followed by a lasting negative virus test in 40% at six months.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseSustained virological response 6 months after treatment
    Study

    n = 15

    Outcome group
    Antiviral activity · Infection

    Measurements

    Patients with sustained response
    40%
    6 months after treatment

    Source sentences

    Summary
    Six months after treatment, six patients (40%), including five with HCV type 1b, showed a sustained response characterized by a negative serum HCV RNA.
    2 context sentences
    Summary · context
    To assess the response in patients with chronic hepatitis C to one year of combination treatment: thymosin alpha 1 (T alpha 1), 1 mg twice weekly, and lymphoblastoid (L)-IFN, 3 MU thrice weekly.
    Summary · context
    Fifteen patients with serum HCV RNA positive chronic hepatitis C were studied.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.